AXGN Stock Overview
Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. More details
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Axogen, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$12.64 |
52 Week High | US$15.90 |
52 Week Low | US$5.55 |
Beta | 1.13 |
11 Month Change | -3.95% |
3 Month Change | 3.10% |
1 Year Change | 114.97% |
33 Year Change | 29.51% |
5 Year Change | -21.83% |
Change since IPO | 366.42% |
Recent News & Updates
Recent updates
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely
Sep 14Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?
Aug 20A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb
Jul 29Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost
Jun 12Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?
Apr 16Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump
Mar 28Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost
Jan 26We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt
Sep 10Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues
Aug 09AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?
Jan 13Is AxoGen (NASDAQ:AXGN) A Risky Investment?
Sep 10AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings
Aug 02Shareholder Returns
AXGN | US Medical Equipment | US Market | |
---|---|---|---|
7D | -0.2% | -1.1% | -2.1% |
1Y | 115.0% | 22.8% | 30.2% |
Return vs Industry: AXGN exceeded the US Medical Equipment industry which returned 22.8% over the past year.
Return vs Market: AXGN exceeded the US Market which returned 30.2% over the past year.
Price Volatility
AXGN volatility | |
---|---|
AXGN Average Weekly Movement | 8.0% |
Medical Equipment Industry Average Movement | 8.0% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AXGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AXGN's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 427 | n/a | www.axogeninc.com |
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
Axogen, Inc. Fundamentals Summary
AXGN fundamental statistics | |
---|---|
Market cap | US$556.26m |
Earnings (TTM) | -US$14.31m |
Revenue (TTM) | US$180.86m |
3.1x
P/S Ratio-38.9x
P/E RatioIs AXGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AXGN income statement (TTM) | |
---|---|
Revenue | US$180.86m |
Cost of Revenue | US$38.43m |
Gross Profit | US$142.43m |
Other Expenses | US$156.74m |
Earnings | -US$14.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.33 |
Gross Margin | 78.75% |
Net Profit Margin | -7.91% |
Debt/Equity Ratio | 50.0% |
How did AXGN perform over the long term?
See historical performance and comparison